Cara Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 6, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 6, 2024

TVRD$1.41+47.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

TABLE OF CONTENTS
· · PAGE

	PART I

Item 1.	Business.	4

Item 1A.	Risk Factors.	23

Item 1B.	Unresolved Staff Comments.	61

Item 1C.	Cybersecurity.	62

Item 2.	Properties.	63

Item 3.	Legal Proceedings.	63

Item 4.	Mine Safety Disclosures.	63

	PART II

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.	64

Item 6.	[Reserved]	65

Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	66

Item 7A.	Quantitative and Qualitative Disclosures About Market Risk.	87

Item 8.	Financial Statements and Supplementary Data.	89

Item 9.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.	145

Item 9A.	Controls and Procedures.	145

Item 9B.	Other Information.	146

Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.	146

	PART III

Item 10.	Directors, Executive Officers and Corporate Governance.	146

Item 11.	Executive Compensation.	146

Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.	146

Item 13.	Certain Relationships and Related Transactions, and Director Independence.	146

Item 14.	Principal Accountant Fees and Services.	146

	PART IV

Item 15.	Exhibit and Financial Statement Schedules.	147

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents